Karonudib has potent anti-tumor effects in preclinical models of B-cell lymphoma

Karonudib has potent anti-tumor effects in preclinical models of B-cell lymphoma

Abstract Chemo-immunotherapy has improved survival in B-cell lymphoma patients, but refractory/relapsed diseases still represent a major challenge, urging for development of new therapeutics. Karonudib (TH1579) was developed to inhibit MTH1, an enzyme preventing oxidized dNTP-incorporation in DNA. M...

Full description

Bibliographic Details
Main Authors: Morten P. Oksvold, Ulrika Warpman Berglund, Helge Gad, Baoyan Bai, Trond Stokke, Idun Dale Rein, Therese Pham, Kumar Sanjiv, Geir Frode Øy, Jens Henrik Norum, Erlend B. Smeland, June H. Myklebust, Thomas Helleday, Thea Kristin Våtsveen
Format: Article
Language:English
Published: Nature Publishing Group 2021-03-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-021-85613-8

Internet

https://doi.org/10.1038/s41598-021-85613-8

Similar Items